Meet Guillermo Montalban Bravo, M.D.
Guillermo Montalban Bravo, M.D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Leukemia, Cancer Medicine, MD Anderson Cancer Center
Dual/Joint/Adjunct Appointment
Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2022 | Educational Commission for Foreign Medical Graduates, Madrid, ES, Steps 1,2 CK , 2 CS and 3, ECFMG Certification |
| 2014 | CNIO Spanish National Center on Investigational Oncology, Madrid, ES, Molecular Oncology, M.S |
| 2010 | Autonomous University of Madrid, Madrid, ES, MD |
| 2004 | King's College Madrid, Madrid, ES, Pre-Medical, BS |
Postgraduate Training
| 2015-2017 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2015 | Certification, ECGMG Certification USMLE, Educational Commission for Foreign Medical Graduates, Philadelpha, Pennsylvania |
| 2013-2013 | Observership, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2013-2013 | Elective Rotation, Molecular Cytogenetics, CNIO Spanish National Center on Investigational Oncology, Madrid |
| 2011-2015 | Specialist, Hematology and Hemotherapy, Social Services and Equality - University Hospital La Paz, Madrid |
| 2011-2015 | Clinical Fellowship, Hematology and Hemotherapy, University Hospital La Paz, Madrid |
Licenses & Certifications
| 2024 | American Board of Internal Medicine |
| 2023 | Texas Medical Board |
| 2015 | Spanish Society of Hematology and Hemotherapy |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Leukemia, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2025
Fellow, Leukemia, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2017
Other Professional Positions
Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017
Observership in the Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2013
Elective Rotation on Molecular Cytogenetics, CNIO Spanish National Center on Investigational Oncology, Madrid, 2013 - 2013
Training in the Specialty of Hematology and Hemptherapy, University Hospital La Paz, Madrid, 2011 - 2015
Editorial Activities
Associate Editor, Frontiers in Oncology, 2022 - Present
Associate Editor, Therapeutic Advances in Hematology, 2017 - 2020
Honors & Awards
| 2020 | The University of Texas MD Anderson Cancer Center Leukemia SPORE, The University of Texas MD Anderson Cancer Center |
| 2018 | Celgene 2018 Future Leaders Award for Clinical Research in Hematology, Celgene Corporation |
| 2017 | The Kimberly-Patterson Fellowship Award for Leukemia Research, The University of Texas MD Anderson Cancer Center |
| 2016 - 2017 | Best Research Fellow, The University of Texas MD Anderson Cancer Center Department of Leukemia |
| 2016 | The ASH Abstract Achievement Award, The American Society of Hematology |
| 2015 - 2016 | Fellow of The Year, The University of Texas MD Anderson Cancer Center Department of Leukemia |
| 2011 | Award to the Best National Academical Record in Medicine, Spanish Royal National Medical Academy |
| 2006 - 2009 | Grant for Exceptional Academical Achievements, Education Council of Madrid, Spain |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Clinical, biological and therapeutic implications of monocytic-differentiation bias in CMML. Conference. Leukemia Research Meeting. Houston, Texas, US.
National Presentations
- 2026. When monocytosis or MDS becomes CMML. Invited. BMFD Scientific Symposium. Washington, US.
- 2025. Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes. Poster. ASCO. Chicago, Illinois, US.
- 2024. Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia. Poster. ASH. San Diego, California, US.
- 2024. Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes. Poster. ASH. San Diego, California, US.
- 2023. Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia. Poster. ASH. San Diego, California, US.
- 2023. NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage. Poster. ASH. San Diego, California, US.
- 2023. Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies. Poster. ASH. San Diego, California, US.
- 2023. Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort. Poster. ASH. San Diego, California, US.
- 2023. Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations. Poster. ASH. San Diego, California, US.
- 2023. Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis. Poster. ASH. San Diego, California, US.
- 2023. Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes. Poster. ASH. San Diego, California, US.
- 2023. Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents. Poster. ASH. San Diego, California, US.
- 2022. A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Poster. ASH. New Orleans, Louisiana, US.
- 2022. A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Poster. ASH. New Orleans, Louisiana, US.
- 2022. RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia. Poster. ASH. New Orleans, Louisiana, US.
- 2021. Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents. Poster. ASH. Atlanta, Georgia, US.
- 2021. Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia. Poster. ASH. Atlanta, Georgia, US.
- 2021. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Poster. ASH. Atlanta, Georgia, US.
- 2021. Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations. Poster. ASH. Atlanta, Georgia, US.
- 2021. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. Poster. ASH. Atlanta, Georgia, US.
International Presentations
- 2025. A Phase I open label study of fostamatinib, a syk inhibitor, inpatients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Poster. EHA 2025. Milan, IT.
- 2023. Analysis of response rates and outcomes in erythroid-predominant myelodysplastic syndromes (MDS) treated with venetoclax-based regimens. Poster. EHA 2023. Frankfurt, DE.
Formal Peers
- 2014. Seminars in Thrombosis. Visiting. Madrid, ES.
- 2014. Spanish Federation of Hemofilia. Visiting. Madrid, ES.
- 2014. Conference on Treatment and prophylactic options for chemotherapy-induced Anemia and Nuetropenia. Visiting. Madrid, ES.
Grant & Contract Support
| Date: | 2026 - 2030 |
| Title: | Multiomic evaluation of cellular states across tissues and RAS pathway inhibition to overcome disease progression in chronic myelomonocytic leukemia |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | FP00028688 |
| Date: | 2025 - 2028 |
| Title: | Evaluating NK cell fitness to overcome disease progression through therapeutic NK-cell modulation in chronic myelomonocytic leukemia |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00026085 |
| Date: | 2025 - Present |
| Title: | Dissecting cell-type composition, tissue cartography and RAS signal dependency to overcome disease progression and tissue infiltration in chronic myelomonocytic leukemia |
| Funding Source: | MDACC |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2025 - 2026 |
| Title: | Targeting BCL-XL-mediated antiapoptotic responses in venetoclax-resistant high-risk erythroid predominant myelodysplastic syndromes |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | PI |
| ID: | FP00026086 |
| Date: | 2025 - 2027 |
| Title: | Targeting nucleoside metabolism and anti-apoptotic mechanisms in high risk CMML |
| Funding Source: | The MDS Foundation |
| Role: | PI |
| ID: | FP00025621 |
| Date: | 2025 - 2027 |
| Title: | CSF1 axis and inflammatory network inhibition in CMML |
| Funding Source: | Sabin Award |
| Role: | PI |
| ID: | RCTS# 65134 |
| Date: | 2025 - 2027 |
| Title: | CSF1 axis and inflammatory network inhibition in CMML |
| Funding Source: | Andrew Sabin Family Foundation Fellowship Award |
| Role: | PI |
| ID: | 4995 |
| Date: | 2025 - Present |
| Title: | Evaluating NK cell fitness to overcome disease progression through therapeutic NK-cell modulation in chronic myelomonocytic leukemia |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP260486 |
| Date: | 2025 - 2028 |
| Title: | 2024-0454: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KER-050 in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia |
| Funding Source: | Keros |
| Role: | PI |
| ID: | RCTS# 64537 |
| Date: | 2025 - 2028 |
| Title: | Targeting nucleoside metabolism and anti-apoptotic mechanisms in high risk CMML |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00023138 |
| Date: | 2025 - 2030 |
| Title: | 2024-1441: A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies |
| Funding Source: | Solu Therapeutics |
| Role: | PI |
| ID: | RCTS# 64551 |
| Date: | 2025 - 2028 |
| Title: | 2024-0493 A Phase 3, multicenter, open label, randomized, non-comparative two arm study of ivosidenib (IVO) monotherapy and ivosidenib in combination with azacitidine (IVO+AZA) in adults with treatment naïve myelodysplastic syndromes (MDS) with an IDH1 mutation |
| Funding Source: | Servier |
| Role: | PI |
| ID: | RCTS# 64451 |
| Date: | 2025 - 2025 |
| Title: | Targeting MEK and FAK signaling in high risk RAS-mutant chronic myelomonocytic leukemia |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| ID: | FP00023897 |
| Date: | 2025 - 2025 |
| Title: | Targeting MEK and FAK signaling in high risk RAS-mutant chronic myelomonocytic leukemia |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | PI |
| ID: | FP00023897 |
| Date: | 2024 - 2031 |
| Title: | 2023-0990 A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial |
| Funding Source: | BMS |
| Role: | Co-PI |
| ID: | AWD00008143 |
| Date: | 2024 - 2028 |
| Title: | 2022-1080 A Pilot, Open-Label Study of Luspatercept for Patients with Lower Risk Myelodysplastic Syndromes (MDS) |
| Funding Source: | BMS |
| Role: | Co-PI |
| ID: | AWD00007884 |
| Date: | 2023 - 2026 |
| Title: | Department of Defense (DOD), A Phase 1b/2a Trial of the Anti-IL1RAP Antibody Nadunolimab in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia |
| Funding Source: | XXXXXXXX |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | Evaluating the role of STING activation in MDS and CMML |
| Funding Source: | Takeda Global Research and Development |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Targeting NF-kB Pathway-Mediated Inflammatory and Anti-Apoptotic Responses in Chronic Myelomonocytic Leukemia |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| Date: | 2022 - 2027 |
| Title: | Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-Program Leader |
| Date: | 2022 - 2026 |
| Title: | 2022-0186 An Open-label, Phase 1b Study of R289, and IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies |
| Funding Source: | Rigel Pharmaceuticals |
| Role: | Co-PI |
| ID: | AWD00006563 |
| Date: | 2022 - Present |
| Title: | Evaluating the role of STING activation in MDS and CMML |
| Funding Source: | Takeda Global Research and Development |
| Role: | PI |
| Date: | 2022 - 2026 |
| Title: | 2022-0139 Evaluating the role of STING activation in MDS and CMML |
| Funding Source: | Takeda |
| Role: | PI |
| Date: | 2022 - 2026 |
| Title: | 2020-0895: Phase I/II Study of Tagraxofusp in combination with Decitabine for patients with Chronic Myelomonocytic Leukemia |
| Funding Source: | Stemline Therapeutics |
| Role: | PI |
| ID: | AWD00005747 |
| Date: | 2022 - 2025 |
| Title: | 2021-0110: Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator’s choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multicenter) (STIMULUS MDS-US) |
| Funding Source: | Novartis |
| Role: | Co-I |
| Date: | 2022 - 2025 |
| Title: | 2020-0895 Phase I/II Study of Tagraxofusp in combination with Decitabine for patients with Chronic Myelomonocytic Leukemia |
| Funding Source: | Stemline Therapeutics |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | A Single-Arm, Open-Label, Phase II Study of Sabatolimab In Combination with Azacitidine and Venetoclax In Adult Participants with High or Very High Risk Myelodysplastic Syndrome (MDS) As Per IPSS-R Criteria |
| Funding Source: | Novartis |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | 2021-0144: A Phase 1/2 study of ALX148 in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML) (ASPEN-05) |
| Funding Source: | ALX Oncology |
| Role: | Co-PI |
| Date: | 2021 - 2024 |
| Title: | 2020-1117: Phase 1/II Open-Label Study of Fostamatinib, a SYK inhibitor, in patients with Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have failed therapy with hypomethylating Agents |
| Funding Source: | Rigel Pharmaceutical |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | 2021-0497: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications |
| Funding Source: | Karopharma |
| Role: | Co-PI |
| Date: | 2021 - 2026 |
| Title: | 2020-0487: Phase I/II Study of SP-2577 (Seclidemstat) in Combination with Azacitidine for patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | Salarius Pharmaceuticals LLC |
| Role: | PI |
| ID: | AWD00005686 |
| Date: | 2021 - 2023 |
| Title: | 2020-0487 Phase I/II Study of SP-2577 (Seclidemstat) in Combination with Azacitidine for patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | Salarius Pharmaceuticals |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | 2020-0983: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma |
| Funding Source: | Incyte |
| Role: | Co-PI |
| Date: | 2021 - 2024 |
| Title: | 2020-0183: A Phase Ib, Multicenter, Open-Label Platform Study of Select Drug Combinations in Adult Patients with Lower Risk (very low, low, or intermediate risk) Myelodysplastic Syndrome |
| Funding Source: | Novartis |
| Role: | Co-PI |
| Date: | 2021 - 2024 |
| Title: | 2020-1119: Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes |
| Funding Source: | Aprea Therapeutics |
| Role: | Co-PI |
| Date: | 2020 - 2023 |
| Title: | 2020-0615: A Phase 1 Study of SEA-CD70 in Myeloid Malignancies |
| Funding Source: | Seattle Genetics |
| Role: | Co-PI |
| Date: | 2020 - 2021 |
| Title: | Identifying Mechanisms of Progression and Failure to Hypomethylating agents in Oligomonocytic Chronic Myelomonocytic Leukemia (CMML) and CMML, National Cancer Institute |
| Funding Source: | National Cancer Institute |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Identifying Mechanisms of Progression and Failure to Hypomethylating agents in Oligomonocytic Chronic Myelomonocytic Leukemia (CMML) and CMML |
| Funding Source: | UTMDACC Leukemia Spore Matching Funds |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Identifying Mechanisms of Progression and Failure to Hypomethylating agents in Oligomonocytic Chronic Myelomonocytic Leukemia (CMML) and CMML |
| Funding Source: | UTMDACC Leukemia SPORE Development Award |
| Role: | PI |
| ID: | FP00012279 |
| Date: | 2020 - 2023 |
| Title: | 2020-0572 AT148002 A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) |
| Funding Source: | ALX Oncology |
| Role: | Co-PI |
| Date: | 2020 - 2026 |
| Title: | 2019-1178: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| Funding Source: | Daiichi Sankyo |
| Role: | PI |
| ID: | RCTS# 58362 |
| Date: | 2020 - 2021 |
| Title: | Identifying Mechanisms of Disease Progression through Single-Cell Transcriptomic and Genomic Characterization of Hematopoietic Stem and Progenitor Cells in Chronic Myelomonocytic Leukemia |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Identifying mechanisms of disease progression through single-cell transcriptomic and genomic characterization of hematopoietic stem and progenitor cells in chronic myelomonocytic leukemia |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Identifying mechanisms of disease progression through single-cell transcriptomic and genomic characterization of hematopoietic stem and progenitor cells in chronic myelomonocytic leukemia |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| ID: | FP00010661 |
| Date: | 2020 - 2023 |
| Title: | 2020-0128: STRATEGIC ALLIANCE: A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naive high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) |
| Funding Source: | Genentech Inc |
| Role: | Co-PI |
| Date: | 2020 - 2021 |
| Title: | Single-Cell Transcriptomic Analysis of Chronic Myelomonocytic Leukemia to Study Cellular Hierarchies and Disease Progression |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Single-cell Transcriptomic analysis of Chronic Myelomonocytic Leukemia to Study Cellular Hierarchies and Disease Progression |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP00010011 |
| Date: | 2020 - 2026 |
| Title: | 2020-0025: Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with (MDS), (CMML), or (AML) |
| Funding Source: | Astex Pharmaceuticals |
| Role: | Co-PI |
| ID: | AWD00004681 |
| Date: | 2020 - 2026 |
| Title: | 2019-1246: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| Funding Source: | Curis |
| Role: | Co-PI |
| ID: | AWD00004684 |
| Date: | 2020 - 2022 |
| Title: | Targeting STING in Myelodysplastic Syndromes |
| Funding Source: | IFM Therapeutics |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Targeting RIPK1-mediated Inflammation and Cell Death in Myelodysplastic Syndromes |
| Funding Source: | Emerson Collective |
| Role: | PI |
| ID: | FP00009602 |
| Date: | 2020 - 2024 |
| Title: | 2020-0025: A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia |
| Funding Source: | Astex Pharmaceuticals |
| Role: | Co-I |
| Date: | 2019 - 2026 |
| Title: | 2019-0760: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies |
| Funding Source: | 2019-0760 |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | 2019-0368: Phase I/II of Venetoclax in combination with Azacitidine in treatment naive and relapse refractory high risk MDS individuals |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2019 - 2026 |
| Title: | 2019-0400: ASTX727-06: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) |
| Funding Source: | Astex Pharmaceuticals |
| Role: | Co-PI |
| Date: | 2019 - 2026 |
| Title: | 2019-0368: Phase I/II of Venetoclax in combination with Azacitidine in treatment naive and relapse refractory high risk MDS individuals |
| Funding Source: | Abbvie/Genentech |
| Role: | Co-PI |
| Date: | 2019 - 2026 |
| Title: | 2019-0400: ASTX727-06: An Open-Label. Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) |
| Funding Source: | Astex Pharmaceuticals |
| Role: | Co-PI |
| ID: | AWD00003723 |
| Date: | 2019 - 2026 |
| Title: | 2018-0911: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate 1) Myelodysplastic Syndromes (MDS) |
| Funding Source: | Jazz Pharmaceuticals |
| Role: | PI |
| ID: | RCTS #: 56059 |
| Date: | 2019 - 2026 |
| Title: | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate 1) Myelodysplastic Syndromes (MDS) |
| Funding Source: | Astex |
| Role: | Co-PI |
| ID: | RCTS# 56533 |
| Date: | 2019 - 2026 |
| Title: | 2018-0179: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects |
| Funding Source: | Celgene Corporation |
| Role: | Co-PI |
| ID: | AWD00003447 |
| Date: | 2019 - 2025 |
| Title: | 2019-0340: A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics of JNJ-64619178, an inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers |
| Funding Source: | Janssen Research and Development, LLC |
| Role: | Co-I |
| Date: | 2019 - 2025 |
| Title: | 2019-0339: Phase 2, Open-Label, Study of Subcutaneous canakinumab, an Anti-IL-1B Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | Novartis |
| Role: | Co-I |
| Date: | 2019 - 2023 |
| Title: | 2019-1178: A Phase1/2 Study of Quizartinib in combination with Azacitidine for Patients with Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia with FLT3 or CBL Mutations |
| Funding Source: | Daichii Sankyo |
| Role: | PI |
| Date: | 2018 - 2025 |
| Title: | 2018-0912: A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes |
| Funding Source: | Aprea Therapeutics |
| Role: | Co-PI |
| Date: | 2018 - 2023 |
| Title: | 2018-0911: Phase 1 Dose Escalation study of CPX-351 for Patients with Int-2 or High risk IPSS Myelodysplastic Syndromes and Chronic myelomonocytic leukemia after failure to hypomethylating agents |
| Funding Source: | Jazz Pharmaceuticals |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | 2018-0009: A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients with Intermediate or High-Risk Myelodysplastic Syndromes |
| Funding Source: | Amphivena Therapeutics |
| Role: | Co-PI |
| Date: | 2017 - 2020 |
| Title: | 2016-0944: A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure |
| Funding Source: | Abbvie |
| Role: | Co-PI |
| Date: | 2017 - 2023 |
| Title: | 2017-0256: A Phase 1b, Multi-Arm, Open-Label Study of PRD001 and/or MBG453 in Combination with Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
| Funding Source: | Novartis |
| Role: | Co-I |
| Date: | 2008 - 2009 |
| Title: | Exceptional Academical Achievements |
| Funding Source: | Madrid Education Council (Madrid, SPAIN) |
| Role: | Collaborator |
| Date: | 2007 - 2008 |
| Title: | Exceptional Academical Achievements |
| Funding Source: | Madrid Education Council (Madrid, SPAIN) |
| Role: | Collaborator |
| Date: | 2006 - 2007 |
| Title: | Exceptional Academical Achievements |
| Funding Source: | Madrid Education Council (Madrid, SPAIN) |
| Role: | Collaborator |
| Title: | 2025-0621 Phase I/II Clinical Trial of Axatilimab, a CSF1R monoclonal antibody, in combination with Ruxolitinib as Therapy for Patients with Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) |
| Funding Source: | Incyte |
| Role: | Co-PI |
| ID: | RCTS# 64894 |
| Title: | 2025-1015 PROSPERA: A randomized phase 2 study in patients with proliferative CMML treated with pacritinib versus hydroxyurea |
| Funding Source: | Theradex Oncology in cooperation with the MDS/MPN International Working Group |
| Role: | PI |
| ID: | RCTS# 65356 |
| Title: | Targeting the cGAS-STING in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Title: | 2020-0546: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome |
| Funding Source: | Forty Seven Inc |
| Role: | Co-I |
| Title: | 2021-0110 Single-arm, open label, ph II study of IV MBG453 (sabatolimab) added to MDS FDA approved Hypomethylating agents of investigator’s choice (IV/SC/Oral) for patients with inter, high or very high risk MDS as per IPSS-R criteria (STIMULUS MDS-US) |
| Funding Source: | Novartis |
| Role: | Co-PI |
| Title: | 2020-1061: Phase 1B/2 Open-Label, Multicenter, Dose Optimization Clinical Study Of The Safety, Tolerability, And Pharmacokinetic And Pharmacodynamic Profiles Of CFI-400945 As A Single Agent Or In Combination With Azacitidine Or Decitabine In Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome Or Chronic Myelomonocytic Leukemia |
| Funding Source: | Treadwell Therapeutics, Inc |
| Role: | Co-PI |
| Title: | 2020-0279: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post¿Polycythemia Vera MF (Post¿ PV-MF), Or Post¿Essential Thrombocythemia MF (Post-ET-MF) Who H |
| Funding Source: | Kartos Therapeutics, Inc |
| Role: | Co-PI |
| Title: | 2017-0886: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic |
| Funding Source: | Astex Therapeutics |
| Role: | Co-PI |
| Title: | 2017-0320: Phase 3 Study (PACIFICA): A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombacythemia |
| Funding Source: | CTI Biopharma |
| Role: | Co-PI |
| Title: | 2020-0522: A phase II pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis |
| Funding Source: | MDACC, BMS |
| Role: | Co-PI |
| Title: | 2020-0180: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (HR-MDS) |
| Funding Source: | AbbVie |
| Role: | Co-PI |
| Title: | 2016-0343: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for patients with MDS |
| Funding Source: | MDACC, Merck & Co |
| Role: | Co-PI |
| Title: | 2016-0757: A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) |
| Funding Source: | AbbVie |
| Role: | Co-PI |
| Title: | DM03-0109: PEG IFN-alpha2a (Pegasys) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia) |
| Funding Source: | N/A |
| Role: | Co-PI |
| Title: | 2020-0129: A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naïve high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) |
| Funding Source: | Astex Pharmaceuticals, Inc, GENENTECH INC |
| Role: | Co-PI |
| Title: | 2018-0943: An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis |
| Funding Source: | Blueprint Medicines Corp |
| Role: | Co-PI |
| Title: | 2018-0907: Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera |
| Funding Source: | Kartos Therapeutics, Inc |
| Role: | Co-PI |
| Title: | 2018-0309: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms |
| Funding Source: | Aprea AB |
| Role: | Co-PI |
| Title: | 2013-0901: Phase 2 Study of SGI-110 in Patients with Higher Risk MDS |
| Funding Source: | Astex Therapeutics, MDACC |
| Role: | Co-PI |
| Title: | 2020-0223: MBG453B12301: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) |
| Funding Source: | Novartis |
| Role: | Co-PI |
| Title: | 2017-0173: A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients .18 Years with Newly Diagnosed Acute Myeloid Leukemia Unfit for Standard Induction Chemotherapy |
| Funding Source: | Helsinn Healthcare |
| Role: | Co-PI |
| Title: | NO TITLE PROVIDED |
| Funding Source: | IdiPAZ, University Hospital La Paz (Madrid, SPAIN) |
| Role: | Co-I |
| ID: | Evaluating Endothelial and Hepatocellular Damage and Liver Fibrosis in Sinusoidal Obstructive Syndrome: Usefulness of Biomarkers and Transition Elastography |
| Title: | 2019-1246: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| Funding Source: | Curis, Inc |
| Role: | Co-I |
| Title: | 2020-0030: A phase II, multicenter, single arm safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy |
| Funding Source: | Novartis |
| Role: | Co-I |
| Title: | 2017-0512: Evaluation Of Ruxolitinib And Thalidomide Combination As A Therapy For Patients With Myelofibrosis |
| Funding Source: | Memorial Sloan Kettering Cancer Center |
| Role: | Co-PI |
| Title: | 2018-0804 An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies |
| Funding Source: | Curis |
| Role: | Co-PI |
| Title: | 2012-0733: A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytope |
| Funding Source: | Celgene |
| Role: | Co-PI |
| Title: | Identifying Mechanisms of Disease Progression through Single-cell Transcriptomic and Genomic Characterization of Hematopoietic Stem and Progenitor Cells in Chronic Myelomonocytic Leukemia |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Title: | 2023-0110: Phase I/II Study of SY-1425 (Tamibarotene) in Combination with Azacitidine and Venetoclax for patients with Higher risk Chronic Myelomonocytic Leukemia |
| Funding Source: | Syros Pharmaceuticals |
| Role: | PI |
| Title: | Targeting RIPK1-Mediated Inflammation and Cell Death in Myelodysplastic Syndromes |
| Funding Source: | Emerson Collective |
| Role: | PI |
| Title: | Analysis and characterization of the hematopoietic stem and progenitor compartments in Myelodyspalstic Syndromes |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Title: | 2020-0573: A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination with Azacitidine in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS) |
| Funding Source: | Innovent |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Bazinet, A, Bataller Torralba, A, Chien, KS, Sasaki, K, Montalban Bravo, G, Hammond, DE, Bouligny, IM, Swaminathan, M, Jen, WY, Kugler, E, Kanagal Shamanna, R, Kadia, TM, Borthakur, G, DiNardo, C, Short, NJ, Pemmaraju, N, Jabbour, EJ, Daver, N, Ravandi-Kashani, F, Urrutia, S, Gener-Ricos, G, Braish, J, Briski, RE, Rodriguez-Sevilla, JJ, Li, Z, Champlin, RE, Shpall, E, Alousi, AM, Oran, B, Hosing, C, Ramdial, JL, Olson, AL, Pierce, S, Chen, J, Kantarjian, HM, Garcia-Manero, G, Popat, UR. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood cancer journal 16(1), 2026. e-Pub 2026. PMID: 41896225.
- Goulart, H, Short, NJ, Borthakur, G, Jain, N, DiNardo, C, Loghavi, S, Khouri, R, Hachem, M, Ravandi-Kashani, F, Daver, N, Kadia, TM, Yilmaz, M, Issa, GC, Bazinet, A, Swaminathan, M, Montalban Bravo, G, Haddad, FG, Garris, R, Kantarjian, HM, Jabbour, EJ. Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia. Blood Advances 10(9):3276-3280, 2026. e-Pub 2026. PMID: 41860396.
- Urrutia, S, Sasaki, K, Bataller Torralba, A, Kantarjian, HM, Montalban Bravo, G, McCloskey, J, Griffiths, EA, Yee, KW, Zeidan, AM, Savona, MR, Oganesian, A, Sano, Y, Keer, HN, Garcia-Manero, G. Decitabine-cedazuridine in patients with MDS and TP53 mutations. Blood Advances 10(3):881-886, 2026. e-Pub 2026. PMID: 41170912.
- Kadia, TM, Jain, A, Rausch, C, Bataller Torralba, A, Ravandi-Kashani, F, Jabbour, EJ, Qiao, W, Borthakur, G, Short, NJ, Montalban Bravo, G, Quesada, AE, Burger, JA, Ferrajoli, A, Wierda, WG, Hosing, C, Kantarjian, HM. Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. Blood Neoplasia 3(1), 2026. e-Pub 2026. PMID: 41536780.
- Chien, KS, Loghavi, S, Sasaki, K, McCue, D, Daver, N, Kadia, TM, Ravandi-Kashani, F, Short, NJ, Issa, GC, Montalban Bravo, G, Haddad, FG, Hammond, DE, Swaminathan, M, Bazinet, A, Bataller Torralba, A, Bouligny, IM, Pierce, S, Garcia-Manero, G, Kantarjian, HM, DiNardo, C. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clinical Lymphoma, Myeloma and Leukemia 26(2):e223-e228.e3, 2026. e-Pub 2026. PMID: 41469316.
- Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
- Goulart, H, Ravandi-Kashani, F, Short, NJ, Jain, N, Daver, N, Kadia, TM, DiNardo, C, Borthakur, G, Takahashi, K, Pemmaraju, N, Haddad, FG, Montalban Bravo, G, Alvarado, Y, Issa, GC, Bataller Torralba, A, Pierce, S, Loghavi, S, Tang, G, Wang, S, Thakral, B, Shpall, E, Champlin, RE, Khouri, IF, Kebriaei, P, Garcia-Manero, G, Sasaki, K, Jabbour, EJ, Senapati, J. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41370732.
- Bazinet, A, Bataller Torralba, A, Montalban Bravo, G, Chien, KS, Sasaki, K, Jen, WY, Swaminathan, M, Kadia, TM, DiNardo, C, Ravandi-Kashani, F, Garcia-Manero, G, Kantarjian, HM. PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. Haematologica 110(12):3125-3128, 2025. e-Pub 2025. PMID: 40605709.
- Jen, WY, Tang, G, Kugler, E, Croden, J, Sasaki, K, Bazinet, A, Bataller Torralba, A, Montalban Bravo, G, Borthakur, G, Toruner, GA, Loghavi, S, Short, NJ, Issa, GC, Bouligny, IM, Pierce, SR, Popat, UR, Pemmaraju, N, Jabbour, EJ, Garcia-Manero, G, Bhalla, K, Ravandi-Kashani, F, Daver, N, DiNardo, C, Kantarjian, HM, Kadia, TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. British Journal of Haematology 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
- Ok, CY, Natu, A, Daneshpajouhnejad, P, Fathalla, LA, Symes, E, Barone, PD, Shestakova, A, Foucar, K, Bueso-Ramos, CE, Montalban Bravo, G, Orazi, A, Patnaik, MM, Hasserjian, RP, Arber, DA, Geyer, JT, Bagg, A, Reichard, KK, Wang, S. Chronic myelomonocytic leukemia in the young (aged 50 years and younger). Cancer 131(22), 2025. e-Pub 2025. PMID: 41236405.
- DiNardo, C, Jen, WY, Montalban Bravo, G, Wang, X, Loghavi, S, Lavu, S, Short, NJ, Chien, KS, Issa, GC, Pemmaraju, N, Yilmaz, M, Andreeff, M, Borthakur, G, Kadia, TM, Daver, N, Garcia-Manero, G, Mill, CP, Su, X, Fiskus, WC, Bhalla, K. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4), 2025. e-Pub 2025. PMID: 40979071.
- Montalban Bravo, G, Loghavi, S, Li, Z, Chien, KS, Kanagal Shamanna, R, Bataller Torralba, A, Natu, A, Gurney, M, Bazinet, A, Hammond, DE, Sasaki, K, Borthakur, G, Swaminathan, M, DiNardo, C, Kadia, TM, Ravandi-Kashani, F, Daver, N, Short, NJ, Pemmaraju, N, Issa, GC, Lasho, T, Finke, C, Al-Kali, A, Csizmar, C, Alkhateeb, HB, Gangat, N, Mangaonkar, AA, Bueso-Ramos, CE, Tefferi, A, Kantarjian, HM, Garcia-Manero, G, Patnaik, MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Advances 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
- Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, Kadia, TM, DiNardo, C, Daver, N, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
- Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Montalban Bravo, G, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Garcia-Manero, G, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
- Tefferi, A, Fathima, S, Abdelmagid, M, Alsugair, AA, Aperna, F, Rezasoltani, M, Yousuf, M, Natu, A, Csizmar, C, Gurney, M, Lasho, T, Finke, C, Kangal-Shamanna, R, Hammond, DE, Chien, KS, Bazinet, A, DiNardo, C, Kadia, TM, Mangaonkar, AA, Daver, N, Pardanani, A, Borthakur, G, Zepeda-Mendoza, CJ, Reichard, KK, He, R, Loghavi, S, Passamonti, F, Ravandi-Kashani, F, Sasaki, K, Larson, DR, Garcia-Manero, G, Onida, F, Gangat, N, Montalban Bravo, G, Patnaik, MM. BLAST. Blood 146(7):874-886, 2025. e-Pub 2025. PMID: 40332442.
- Kadia, TM, Jen, WY, Bataller Torralba, A, Bazinet, A, Borthakur, G, Jabbour, EJ, Qiao, W, Short, NJ, Takahashi, K, Issa, GC, DiNardo, C, Montalban Bravo, G, Pemmaraju, N, Tran, A, Bharathi, V, Loghavi, S, Alousi, AM, Popat, UR, Daver, N, Ravandi-Kashani, F, Kantarjian, HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. American journal of hematology 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
- Csizmar, C, Natu, A, Gurney, M, Fathima, S, Alsugair, AA, Kanagal Shamanna, R, Loghavi, S, Bazinet, A, Chien, KS, Hammond, DE, DiNardo, C, Kadia, TM, Ravandi-Kashani, F, Pemmaraju, N, Sasaki, K, Lasho, T, Finke, C, Al-Kali, A, Alkhateeb, HB, Begna, K, Gangat, N, Hefazi Torghabeh, M, Matin, A, Mangaonkar, AA, Saliba, AN, Tefferi, A, Garcia-Manero, G, Kantarjian, HM, Komrokji, RS, Xie, Z, Ali, NA, Sallman, D, Padron, E, Montalban Bravo, G, Patnaik, MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
- Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Daver, N, Senapati, J, Kantarjian, HM, Wang, B, Reville, PK, Loghavi, S, Yilmaz, M, DiNardo, C, Kadia, TM, Yassouf, MY, Maiti, A, Arora, S, Montalban Bravo, G, Tang, G, Borthakur, G, Sasaki, K, Pemmaraju, N, Alvarez, J, Nogueras Gonzalez, G, Ning, J, Issa, GC, Konopleva, M, Andreeff, M, Ravandi-Kashani, F, Garcia-Manero, G, Abbas, HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
- Senapati, J, Loghavi, S, Garcia-Manero, G, Tang, G, Kadia, TM, Short, NJ, Abbas, HA, Arani, N, DiNardo, C, Borthakur, G, Pemmaraju, N, Oran, B, Shpall, E, Popat, UR, Champlin, RE, Pierce, S, Arora, S, Issa, GC, Yilmaz, M, Patel, KP, Takahashi, K, Montalban Bravo, G, Hammond, DE, Haddad, FG, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
- Saul, EE, Urrutia, S, Yang, H, Montalban Bravo, G, Tang, G, Toruner, GA, Patel, KP, Luthra, R, Bueso-Ramos, CE, Wang, S, Chien, KS, Sasaki, K, Atluri, H, Goulart, H, Thakral, B, Garcia-Manero, G, Kanagal Shamanna, R. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. JNCCN Journal of the National Comprehensive Cancer Network 23(6), 2025. e-Pub 2025. PMID: 40345240.
- Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
- Sasaki, K, Garcia-Manero, G, Nigo, M, Jabbour, EJ, Ravandi-Kashani, F, Wierda, WG, Jain, N, Takahashi, K, Montalban Bravo, G, Daver, N, Thompson, PA, Pemmaraju, N, Kontoyiannis, DP, Sato, J, Karimaghaei, S, Soltysiak, KA, Raad, II, Kantarjian, HM, Carter, B. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clinical Lymphoma, Myeloma and Leukemia 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
- Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Takaoka, K, Komrokji, RS, Chien, KS, Montalban Bravo, G, Salman, JB, Urrutia, S, Bataller Torralba, A, Bazinet, A, Kekedjian, J, Al Ali, NH, Sallman, D, Padron, E, Xie, Z, Kanagal Shamanna, R, Tang, G, Yang, H, Rodriguez-Sevilla, JJ, Garcia-Manero, G, Sasaki, K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leukemia Research 150, 2025. e-Pub 2025. PMID: 39938357.
- Gurashi, K, Wang, YH, Amaral, FM, Spence, K, Cant, R, Yao, CY, Lin, CC, Wirth, C, Wedge, DC, Montalban Bravo, G, Colla, S, Tien, HF, Somervaille, TC, Batta, K, Wiseman, DH. An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia. Cell Reports Medicine 6(2), 2025. e-Pub 2025. PMID: 39892394.
- Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Lachowiez, C, Asimomitis, G, Bernard, E, Devlin, SM, Tazi, Y, Creignou, M, Germing, U, Gattermann, N, Gilkes, A, Thomas, I, Bullinger, L, Döhner, K, Malcovati, L, Othman, J, Dillon, R, Eisfeld, AK, Nicolet, D, Issa, GC, Daver, N, Kadia, TM, DiNardo, C, Ravandi-Kashani, F, Garcia-Manero, G, Montalban Bravo, G, Russell, N, Cazzola, M, Döhner, H, Huntly, BJ, Hasserjian, RP, Hellström-Lindberg, E, Papaemmanuil, E, Loghavi, S. Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States. Blood Cancer Discovery 6(5):425-436, 2025. e-Pub 2025. PMID: 40608896.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Park, GS, Atluri, H, DiNardo, C, Guillroy, B, Horak, J, Apostolidou, E, Buni, M, Montalban Bravo, G, Pemmaraju, N. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies. Leukemia Research Reports 23, 2025. e-Pub 2025. PMID: 39691506.
- Nahmod, KA, Miranda, R, Vega Vazquez, F, Thakral, B, Pemmaraju, N, Montalban Bravo, G, Loghavi, S, Jelloul, FZ, Wang, W, Wang, S, Muzzafar, T, Patel, KP, Bueso-Ramos, CE, Medeiros, LJ, Kanagal Shamanna, R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation. Leukemia and Lymphoma 66(4):764-772, 2025. e-Pub 2025. PMID: 39704386.
- McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
- Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Sasaki, K, Kantarjian, HM, Montalban Bravo, G, Hammond, DE, Jabbour, EJ, Kanagal Shamanna, R, Chien, KS, Garcia-Manero, G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(9):629-633, 2024. e-Pub 2024. PMID: 38777652.
- Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. e-Pub 2024. PMID: 38744144.
- Montalban Bravo, G, Thongon, N, Rodriguez-Sevilla, JJ, Ma, F, Ganan Gomez, I, Yang, H, Kim, YJ, Ademà Llobet, V, Wildeman, B, Tanaka, T, Darbaniyan, F, Al-Atrash, G, Dwyer, KC, Loghavi, S, Kanagal Shamanna, R, Song, X, Zhang, J, Takahashi, K, Kantarjian, HM, Garcia-Manero, G, Colla, S. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38781960.
- Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):JCO2301911, 2024. e-Pub 2024. PMID: 38277619.
- Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38(5):1178-1181, 2024. e-Pub 2024. PMID: 38418609.
- Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
- Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
- Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99(4):792-796, 2024. e-Pub 2024. PMID: 38361282.
- Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, Montalban-Bravo G, Adema V, Wildeman B, Kanagal-Shamanna R, Bazinet A, Chifotides HT, Thongon N, Calvo X, Hernández-Rivas JM, Díez-Campelo M, Garcia-Manero G, Colla S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun 15(1):2428, 2024. e-Pub 2024. PMID: 38499526.
- Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 204(3):898-909, 2024. e-Pub 2023. PMID: 37946611.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med 13(5):e7093, 2024. e-Pub 2024. PMID: 38497538.
- Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
- Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Sasaki, K, Morita, K, Kantarjian, HM, Garcia-Manero, G, Jabbour, EJ, Ravandi, F, Konopleva, M, Borthakur, G, Wierda, WG, Daver, N, Takahashi, K, DiNardo, C, Montalban Bravo, G, Issa, GC, Pierce, S, Soltysiak, KA, Tingen, MS, Cortes, JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma, Myeloma and Leukemia 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
- Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
- Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
- Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
- DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
- Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
- Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
- Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv, 2023. e-Pub 2023. PMID: 37066354.
- Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
- Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic Features and Clinical Outcomes in Newly Diagnosed Myelodysplastic Syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
- Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127:107044, 2023. e-Pub 2023. PMID: 36801700.
- Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046645.
- Thongon N, Ma F, Lockyer P, Baran N, Liu J, Jackson C, Rose A, Wildeman B, Marchesini M, Marchica V, Storti P, Giuliani N, Ganan-Gomez I, Adema V, Qing Y, Ha M, Fonseca R, Class C, Tan L, Kanagal-Shamanna R, Nolasco DB, Cerchione C, Montalban-Bravo G, Santoni A, Bueso-Ramos C, Konopleva M, Lorenzi P, Garcia-Manero G, Manasanch E, Viale A, Chesi M, Colla S. Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. bioRxiv, 2023. e-Pub 2023. PMID: 36865225.
- Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
- Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
- Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
- Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
- Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):1-11, 2022. e-Pub 2022. PMID: 36059252.
- Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
- Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov 3(6):554-567, 2022. e-Pub 2022. PMID: 35926182.
- Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
- Darbaniyan F, Zheng H, Kanagal-Shamanna R, Lockyer P, Montalban-Bravo G, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Class C, Ganan-Gomez I, Do KA, Garcia-Manero G, Wei Y. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol 115:44-53, 2022. e-Pub 2022. PMID: 36150563.
- Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, Kontoyiannis DP. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis 75(9):1503-1510, 2022. e-Pub 2022. PMID: 35325094.
- Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
- Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
- Kim, K, Ong, F, Montalban Bravo, G, Kanagal Shamanna, R, Kadia, TM, Jabbour, EJ, Alvarado, Y, Sasaki, K, Dong, XQ, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Chien, KS, Garcia-Manero, G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 22:S310, 2022. e-Pub 2022. PMID: 36163955.
- Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
- Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. e-Pub 2022. PMID: 36163972.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
- Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR, Working Group MI. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC Cancer 22(1):1013, 2022. e-Pub 2022. PMID: 36153475.
- Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
- Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
- Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol 35(9):1212-1219, 2022. e-Pub 2022. PMID: 35504958.
- Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
- DiNardo, C, Lachowiez, C, Takahashi, K, Loghavi, S, Kadia, TM, Daver, N, Xiao, L, Adeoti, M, Short, NJ, Sasaki, K, Wang, S, Borthakur, G, Issa, GC, Maiti, A, Alvarado, Y, Pemmaraju, N, Montalban Bravo, G, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. American journal of hematology 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
- Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia 36(8):2097-2107, 2022. e-Pub 2022. PMID: 35697791.
- Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
- Tashakori M, Wang W, Kadia TM, Daver NG, Montalban-Bravo G, Loghavi S, Wang SA, Medeiros LJ, Ravandi F, Khoury JD. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res 118:106860, 2022. e-Pub 2022. PMID: 35636055.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
- Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia 36(4):1189-1192, 2022. e-Pub 2022. PMID: 34975158.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
- Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Montalban Bravo G, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2021. PMID: 34716921.
- Sallman DA, Bejar R, Montalban-Bravo G, Kurtin SE, List AF, Garcia-Manero G, Nimer SD, O'Connell CL, Schaar D, Butchko J, Iraca T, Searle S. Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning. Leuk Res Rep 17:100328, 2022. e-Pub 2022. PMID: 35663282.
- Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun 12(1):6850, 2021. e-Pub 2021. PMID: 34824242.
- Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
- Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
- Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
- Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
- DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
- Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
- Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
- Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
- Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud 7(3), 2021. e-Pub 2021. PMID: 34117074.
- Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
- Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
- Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
- Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
- Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
- Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
- Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
- Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
- Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res 101:106511, 2021. e-Pub 2021. PMID: 33517186.
- Ramos Perez J, Montalban-Bravo G. Emerging drugs for the treatment of chronic myelomonocytic leukemia. Expert Opin Emerg Drugs 25(4):515-529, 2020. e-Pub 2020. PMID: 33280448.
- Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
- Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
- Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management. Am J Hematol 95(11):1399-1420, 2020. e-Pub 2020. PMID: 32744763.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
- DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
- Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
- Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
- Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma 61(6):1-7, 2020. e-Pub 2020. PMID: 32036728.
- Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
- Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34(3):872-881, 2020. e-Pub 2020. PMID: 31719677.
- Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765-774, 2020. e-Pub 2020. PMID: 31742675.
- Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
- Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
- Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. The role of TGF-β in hematopoiesis and myeloid disorders. Leukemia 33(5):1076-1089, 2019. e-Pub 2019. PMID: 30816330.
- Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol, 2019. e-Pub 2019. PMID: 31156799.
- Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. e-Pub 2019. PMID: 30902805.
- Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. e-Pub 2019. PMID: 30861111.
- Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
- Burgos S, Montalban-Bravo G, Fuente L, Jabbour EJ, Kanagal-Shamanna R, Soltysiak KA, Garcia-Manero G, Mela-Osorio MJ. Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine (Baltimore) 98(1):e14011, 2019. e-Pub 2019. PMID: 30608448.
- Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol 14(10):979-993, 2018. e-Pub 2018. PMID: 29543066.
- Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol 25(2):146-153, 2018. e-Pub 2018. PMID: 29266015.
- Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
- Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol 93(1):129-147, 2018. e-Pub 2018. PMID: 29214694.
- Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
- Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
- Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol 92(7):599-606, 2017. e-Pub 2017. PMID: 28370097.
- Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
- Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
- Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 123(6):994-1002, 2017. e-Pub 2017. PMID: 28094841.
- Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2017. PMID: 27795561.
- Montalban-Bravo G, Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. N Engl J Med 376(8):796-7, 2017. e-Pub 2017. PMID: 28229579.
- Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
- Montalbán-Bravo G, Kerguelen Fuentes AE, Canales Albendea MA, Álvarez Román M, Martín Salces M, Jiménez-Yuste V. Light-chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A. Haemophilia 21(1):e92-4, 2015. e-Pub 2015. PMID: 25430974.
- Romero Fernández E, Bravo GM, Gallastegui RA, De la Rúa Fernández AR. Lymphocyte recovery and infused CD34+ cells dose: Effect on the evolution after stem cell autotransplantation. Leuk Res Rep 2(2):54-7, 2013. e-Pub 2013. PMID: 24371781.
- Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia T, Kanagal-Shamanna R, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances.
Review Articles
- Bazinet, A, Montalban Bravo, G. New Approaches to Myelodysplastic Syndrome Treatment. Current treatment options in oncology 23(5):668-687, 2022. e-Pub 2022. PMID: 35320468.
- Hammond D, Montalban-Bravo G. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep 16(5):405-417, 2021. e-Pub 2021. PMID: 34499330.
- Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2021. PMID: 32392559.
- Montalban-Bravo G, Garcia-Manero G. MDS/MPN-RS-T justified inclusion as a unique disease entity?. Best Pract Res Clin Haematol 33(2):101147, 2020. e-Pub 2020. PMID: 32460979.
- Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol 10:2040620719847059, 2019. e-Pub 2019. PMID: 31156799.
- Alfonso A, Montalban-Bravo G, Garcia-Manero G. Current management of patients with chronic myelomonocytic leukemia. Curr Opin Oncol 29(1):79-87, 2017. e-Pub 2017. PMID: 27849645.
- Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 29(4):760-9, 2015. e-Pub 2015. PMID: 25142817.
- Bravo GM, Lee E, Merchan B, Kantarjian HM, García-Manero G. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol 166(5):646-59, 2014. e-Pub 2014. PMID: 24903747.
Abstracts
- Sasaki K, Kantarjian H, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Montalban-Bravo G, Rios MB, Pierce S, Sakurai K, Jabbour E, Cortes J. Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood 2018 132:3026, 2018. e-Pub 2018.
- Bose P, McCue D, Wiederhold N, Katia T, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson P, Pemmaraju N, Daver N, Burger J, Cortes J, Garcia-Manero G, Verstovsek S, Konopleva M, Jain N, DiNardo C, Alvarado Y, Naqvi K, Kornblau S, Ferrajoli A, Wierda W, Estrov Z, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins C, Pierce S, Kantarjian H, Kontoyiannis D. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 2018 132:2674, 2018. e-Pub 2018.
- Rausch CR, Paul S, Montalban-Bravo G, Jabbour E, Daver N, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Cortes J, Kadia T, Konopleva M, Ohanian M, Pierce S, Gasior Y, Benton CB, Takahashi K, Masarova L, Andreef M, Estrov Z, Kantarjian H, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndromes (MDS) Treated with Nivolumab and Ipilimumab. Blood 2018 132:4367, 2018. e-Pub 2018.
- Sasaki K, Kanagal-Shamana R, Montalban-Bravo G, Assi R, Naqvi K, Alfonso-Pierola A, Yilmaz M, Short N, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, DiNardo C, Nogueras-Gonzalez GM, Abaza Y, Devendra KC, Chamoun K, Sakurai K, Patel K, Cortes J, Kantarjian H, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patietns with Newly diagnosed Acute Myeloid Leukemia. Blood 2018 132:4367, 2018. e-Pub 2018.
- Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver N, Jabbour E, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes J, Kadia T, Konopleva M, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos C, Kanagal-Shamana R, Patel K, Kantarjian H. A Phase II Study of Nivlumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndromes (MDS). Blood 2018 132:465, 2018. e-Pub 2018.
- Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden K, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Cortes J, Jabbour E, Naqvi K, DiNardo C, Benton CB, Pemmaraju N, Kadia T, Ohanian M, Pierce S, Kantarjian H. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients with Previously Untreated Myelodysplastic Syndromes. Blood 2018 132:232, 2018. e-Pub 2018.
- Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes J, Kadia T, Konopleva M, Raush CR, Gasior Y, Kantarjian H. Double Immune Checkpoint Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood 2018 132:1831, 2018. e-Pub 2018.
- Tallis E, Benton CB, Khan A, Assi R, DiNardo C, Hornbaker M, Kendall Major C, Boddu P, Kanagal-Shamana R, Patel K, Daver N, Takahashi K, Montalban-Bravo G, Kadia T, Konopleva M, Andreeff M, Kantarjian H, Garcia-Manero G. Diverse Landscape of TET2 Variants in MDS and AML. Blood 2018 132(1479), 2018. e-Pub 2018.
- Richard-Carpentier G, Kantarjian H, Short N, Ravandi F, Ferrajoli A, Schroeder H, Khouri M, Garcia-Manero G, Montalban-Bravo G, Cortes J, Jain N, Konopleva M, Takahashi K, Sasaki K, Garries RE, Jabbour E. A Phase II Study of the Hyper-CVAD Regimen In Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Blood 2018 132:32, 2018. e-Pub 2018.
- Kanagal-Shamana R, Sasaki K, Montalban-Bravo G, Benton CB, Jabbour E, Borthakur G, Kadia T, Bueso-Ramos C, Patel K, Ravandi F, Kantarjian H, Garcia-Manero G. Evolutionay Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood 2018 132:1820, 2018. e-Pub 2018.
- Ganan-Gomez I, Alfonso A, Yang H, Santoni A, Marchica V, Fiorini E, Montalban-Bravo G, Ogoti Y, Manyam G, Jiang S, Bao N, Jackson C, Rose A, Kanagal-Shamana R, Bueso-Ramos C, Cambo B, Giuliani N, Crugnola M, Konopleva M, Clise-Dwyer K, Garcia-Manero G, Colla S. Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood 2018 132:1798, 2018. e-Pub 2018.
- Aboudalle I, Kantarjian H, Short N, Ravandi F, Sasaki K, Garcia-Manero G, Montalban-Bravo G, Cortes J, Benton CB, Issa G, Khouri M, Nasmas P, O’Brien S, Jabbour E. Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed B-Precursor Acute Lymphoblastic Leukemia. Blood 2018 132:4017, 2018. e-Pub 2018.
- Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras-Gonzalez GM, Kanagal-Shamana R, Patel K, Kantarjian H, Garcia-Manero G. Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndromes. Blood 2018 132:1814, 2018. e-Pub 2018.
- Yang H, Fang Z, Clise-Dwyer K, Ruisaard K, Colla S, Ganan-Gomez I, Montalban-Bravo G, Soltysiak K, Daver N, Jabbour E, Kantarjian H, Garcia-Manero G. Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitidine in Combination with Nivolumab and/or Ipilimumab. Blood 2018 132:1807, 2018. e-Pub 2018.
- Naqvi K, Sasaki K, Montalban-Bravo G, Teach MS, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis. Blood 2018 132:5513, 2018. e-Pub 2018.
- Montalban-Bravo G, Benton CB, Kanagal-Shamana R, Sasaki K, Assi R, Kadia T, Ravandi F, Ganan-Gomez I, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos C, Kornblau S, Patel K, Colla S, Kantarjian H, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood 2018 132:2791, 2018. e-Pub 2018.
- Montalban-Bravo G, Kanagal-Shamna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Naqvi K, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Mutational and Clonal landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood 2018 132:1514, 2018. e-Pub 2018.
- Jabbour EJ, Short NJ, Montalban Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes JE, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian HM, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130(No. 13):1514-1522, 2017. e-Pub 2017.
- Assi RE, Pierola AA, Devendra KC, Abaza YM, Zahr AA, Chamoun K, Montalban-Bravo G, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, Dinardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Futreal A, Kantarjian HM, Garcia-Manero G, Pierce S. Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). J Clin Oncol suppl(35), 2017. e-Pub 2017.
- Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, Dinardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G. Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. J Clin Oncol suppl(35), 2017. e-Pub 2017.
- Montalban-Bravo G, Pierola AA, Takahashi K, Konopleva M, Jabbour E, Borthakur G, Daver NG, Dinardo CD, Estrov Z, Kadia TM, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Kantarjian HM, Patel K, Garcia-Manero G. Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms with normal karyotype. J Clin Oncol suppl(35), 2017. e-Pub 2017.
- Pierola AA, Montalban-Bravo G, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, Dinardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of the type of first-cancer therapy in therapy-related myelodysplastic syndromes outcomes. J Clin Oncol suppl(35), 2017. e-Pub 2017.
- Montalban Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian HM, Young KH, Garcia-Manero G, and Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(No. 18):2584-2587, 2017. e-Pub 2017.
- Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alavarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JC, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130(Suppl 1):2967, 2017. e-Pub 2017.
- Alfonso Pierola A, Assi R, KC D, Abaza Y, Abou Zahr A, Chamoun K, Montalban Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel KP, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood 130(Suppl 1 3852), 2017. e-Pub 2017.
- Naqvi K, Montalban Bravo G, Alfonso Pierola A, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, Gonzalez GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1 4258), 2017. e-Pub 2017.
- Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, and Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 2017 130(Suppl 1):2967, 2017. e-Pub 2017.
- Pierola AA, Assi R, Devendra KC, Abaza Y, Abou Zahr A, Chamoun K, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel KP, Futreal A, Pierce S, Kantarjian HM, and Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood 2017 130(Suppl 1):3852, 2017. e-Pub 2017.
- Naqvi K, Montalban Bravo G, Pierola AA, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, Nogueras González G, Kantarjian HM, and Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 2017 130(Suppl 1):4258, 2017. e-Pub 2017.
- Ganan-Gomez I, Alfonso A, Ogoti Y, Yang H, Montalban Bravo G, Yu AC, Marchesini M, Bueso-Ramos C, Takahashi K, Clise-Dwyer K, Garcia-Manero G, and Colla S. Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood 128(No. 22):4310, 2016. e-Pub 2016.
- Alfonso Pierola A, Marchesini M, Takahashi K, Ganan-Gomez I, Fiorini E, Ogoti Y, Irles E, Montalban Bravo G, Sofia S, Dwyer KC, Garcia-Manero G, and Colla S. The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood 128(No. 22):958, 2016. e-Pub 2016.
- Abaza Y, Jabbour EJ, Verstovsek S, Estrov Z, Ravandi F, Borthakur G, Kadia TM, Daver N, DiNardo CD, Bueso-Ramos CE, Hidalgo JE, Schneider H, Montalban Bravo G, Alfonso A, Wei Y, Kantarjian HM, and Garcia-Manero G. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood 2016 128(22):4318, 2016. e-Pub 2016.
- Punit JL, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Montalban-Bravo G, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia After Frontline Therapy Failure. Blood 126(23):3718, 2015. e-Pub 2015.
- Montalban-Bravo G, Kantarjian HM, Jain PL, Garcia-Manero G, Ravandi F, Cortes JE. Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood 126(23):2503, 2015. e-Pub 2015.
- Montalban-Bravo G, Kantarjian HM, Cortes JE, Ravandi F, Garcia-Manero G, Punit J. Clinical Impact of First Complete Remission (CR1) Duration on Oucome of Patients with Relapsed Philadelphia Negative Pre-8 Acute Lymphoblastic Leukemia (ALL). Blood 126(23):2504, 2015. e-Pub 2015.
- Montalban-Bravo G, Garcia-Manero G, Short NJ, Sasaki K, Sekeres MA, Komrokji RS. Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (Pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood 126(23):2877, 2015. e-Pub 2015.
- Short NJ, Garcia-Manero G, Montalban-Bravo G, Sasaki K, Sekeres MA, Komrokji RS. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with low or Intermediate-1-Risk Myelodysplastic Syndromes (MDS9: A Report on Behalf of the MDS Clinical Research Consortium. Blood 126(23):94, 2015. e-Pub 2015.
Book Chapters
- Montalban-Bravo G, Garcia-Manero G. In: The Myelodysplastic Syndromes. In: Wintrobe’s Clinical Hematology 14th Edition. Wintrobe’s Clinical Hematology 14th Edition, 2019.
- Canales Albendea M, Montalban Bravo G. Leucemias agudas. In: Cliniguía 2012: Actualización de Diagnóstico y Terapeútica 7ª edición. Seventh. Elsevier Espana, 2017.
- Montalban Bravo G, Garcia-Manero G. Targeted Therapy in Myelodysplastic Syndromes. In: Targeted Therapy in Translational Cancer Research. Third. John Wiley & Sons, Inc, 162-168, 2015.
- Canales AM, Bravo M, G. Leucemias agudas. In: Cliniguía 2012: Actualización de Diagnóstico y Terapeútica 7ª edición, 2012.
Letters to the Editor
- Jabbour, EJ, Goulart, H, Sasaki, K, Rausch, C, Jain, N, Kadia, TM, DiNardo, C, Daver, N, Pemmaraju, N, Ravandi-Kashani, F, Montalban Bravo, G, Garcia-Manero, G, Hammond, DE, Swaminathan, M, Hachem, M, Khouri, R, Ohanian, M, Garris, R, Short, NJ, Kantarjian, HM. Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American journal of hematology 101: 1729-1736, 2026.
- Chien, KS, Li, Z, Lanino, L, Ali, NA, Urrutia, S, Bataller Torralba, A, Kanagal Shamanna, R, Loghavi, S, Lyu, Y, Abdelhakeem, AA, Abuasab, T, Almanza, E, Ricos, GG, Bazinet, A, Campagna, A, Maggioni, G, Padron, E, Xie, Z, Montalban Bravo, G, Short, NJ, Jabbour, EJ, Kadia, TM, Ravandi-Kashani, F, Borthakur, G, DiNardo, C, Hammond, DE, Swaminathan, M, Sasaki, K, Dong, XQ, Pierce, S, Sallman, D, Kantarjian, HM, Della Porta, M, Garcia-Manero, G, Komrokji, RS. Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms. Leukemia 40: 841-844, 2026.
- Azevedo, RS, Braish, J, Gener-Ricos, G, Tang, G, Sasaki, K, Montalban Bravo, G, Jabbour, EJ, Ohanian, M, Yilmaz, M, Haddad, FG, Chien, KS, Ishizawa, J, Short, NJ, Maiti, A, Swaminathan, M, Kantarjian, HM, Borthakur, G, Kadia, TM. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leukemia and Lymphoma 67: 220-224, 2026.
- Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
- Bazinet, A, Montalban Bravo, G, Bataller Torralba, A, Hammond, DE, Loghavi, S, Chien, KS, Sasaki, K, Bouligny, IM, Swaminathan, M, Jen, WY, Popat, UR, Kadia, TM, DiNardo, C, Jabbour, EJ, Short, NJ, Daver, N, Ravandi-Kashani, F, Garcia-Manero, G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39: 2820-2824, 2025.
- Jen, WY, Loghavi, S, Bazinet, A, Bataller Torralba, A, Bouligny, IM, Daver, N, Issa, GC, Arani, N, Almanza-Huante, E, Maiti, A, Montalban Bravo, G, Borthakur, G, Short, NJ, Pierce, SR, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C, Kadia, TM. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies. American journal of hematology 100: 2118-2122, 2025.
- Croden, J, Jen, WY, Marvin-Peek, J, Xiao, L, Bouligny, IM, Loghavi, S, Borthakur, G, Daver, N, Abbas, HA, Takahashi, K, Sasaki, K, Pemmaraju, N, Short, NJ, Hammond, DE, Jabbour, EJ, Masarova, L, Chien, KS, Issa, GC, Montalban Bravo, G, Yilmaz, M, Maiti, A, Alvarado, Y, Garcia-Manero, G, Ravandi-Kashani, F, Konopleva, M, Kantarjian, HM, Kadia, TM, DiNardo, C. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39: 2538-2541, 2025.
- Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
- Chien, KS, Braish, J, Li, Z, Loghavi, S, Bataller Torralba, A, Montalban Bravo, G, Sasaki, K, Kanagal Shamanna, R, Takahashi, K, DiNardo, C, Swaminathan, M, Kantarjian, HM, Garcia-Manero, G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39: 1269-1272, 2025.
- Tremblay, D, Csizmar, C, DiNardo, C, Ball, S, Rippel, N, Hammond, DE, Kadia, TM, Ravandi, F, Chien, KS, Van Hyfte, G, Mazumdar, M, Saliba, AN, Mangaonkar, AA, Lasho, T, Al-Kali, A, Kremyanskaya, M, Feld, J, Silverman, LR, Komrokji, RS, Mascarenhas, J, Padron, E, Garcia-Manero, G, Sallman, D, Patnaik, MM, Montalban Bravo, G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia. Leukemia 39: 257-260, 2025.
- Kontoyiannis, PD, Peddireddy, A, Sasaki, K, Chien, KS, Senapati, J, Montalban Bravo, G, DiNardo, C, Borthakur, G, Kanagal-Shamanna, R, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G, Urrutia, S. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. Leukemia Research 147, 2024.
- Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
- Csizmar, C, Gurney, M, Kanagal-Shamanna, R, Chien, KS, Hammond, DE, Lasho, T, Finke, C, Dean, C, Natu, A, Mangaonkar, AA, Al-Kali, A, Gangat, N, Tefferi, A, Alkhateeb, HB, Garcia-Manero, G, Komrokji, RS, Ali, NA, Padron, E, Montalban Bravo, G, Patnaik, MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 109: 3419-3425, 2024.
- Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, Kadia, TM, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia 24: 732-735, 2024.
- Paul, S, Kantarjian, HM, Sasaki, K, Marx, K, Jain, N, Savoy, JM, DiPippo, AJ, Jammal, N, Montalban Bravo, G, Kadia, TM, Garcia-Manero, G, Short, NJ, Ravandi-Kashani, F, Jabbour, EJ. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American journal of hematology 98: E11-E14, 2023.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Leukemia 35: 1494-1499, 2021.
- Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol, 2021.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96: E50-E53, 2021.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in Oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol, 2020.
- Montalban-Bravo G, Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. Engl J Med: 796-798, 2017.
- Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129: 2584-2587, 2017.
Patient Reviews
CV information above last modified July 22, 2026